CORDIS
EU research results

CORDIS

English EN

Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe

Project information

Grant agreement ID: 602714

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 032 384

  • EU contribution

    € 5 443 350

Coordinated by:

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy

Objective

"Traumatic brain injury (TBI) is among the leading causes of death and disability and the main cause of death among the under-45s. Most patients with moderate to severe TBI are admitted to intensive care units (ICUs)
The “PROSAFE” ICU network was recently established in 6 European countries through EU funding (PHEA 2007331), and has continued to collect high-quality data beyond the grant duration. In 2011, 225 ICUs had joined PROSAFE, recruiting a total of 73,163 patients, 2,694 of whom were admitted for TBI. Hence the network can expect to enrol 7-9,000 moderate to severe TBI patients in 4 years. The PROSAFE consortium has already focused attention on TBI and has just started collecting additional information on this condition in order to develop a prognostic model to identify centres of excellence in TBI management
Aims of proposal are to consolidate the existing network in order to better describe the epidemiology of moderate-severe TBI in 7 countries (Greece has now joined the consortium); build a prognostic model based on short- and long-term outcome measures; identify most effective clinical interventions for optimally treating TBI patients, and recognize the determinants of optimal vs suboptimal performance
All TBI-CDEs endorsed by InTBIR will be collected, along with other items needed to develop a sensible prognostic model, permitting the consortium to join forces with international collaborative initiatives in the field
Availing of the coordinating institute’s biobank and consolidated expertise in biochemical and genetic biomarkers, the aim is to identify prognostic markers and underlying genetic factors influencing response to treatment and final outcome
The PROSAFE consortium is thus in a position to guarantee superior quality data collection in 7 countries and ensure it continues beyond the life of the project. These conditions are essential if the consortium is to contribute to Europe playing a key role in the success of the InTBIR initiative"

Coordinator

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Address

Via Mario Negri 2
20156 Milano

Italy

Activity type

Research Organisations

EU Contribution

€ 2 386 582

Administrative Contact

Guido Bertolini (Dr.)

Participants (8)

SEMMELWEIS EGYETEM

Hungary

EU Contribution

€ 519 726

WARSZAWSKI UNIWERSYTET MEDYCZNY

Poland

EU Contribution

€ 478 470

SPLOSNA BOLNISNICA NOVO MESTO

Slovenia

EU Contribution

€ 256 671

UNIVERZITETNI KLINICNI CENTER LJUBLJANA

Slovenia

EU Contribution

€ 337 671

EDEX - EDUCATIONAL EXCELLENCE CORPORATION LIMITED

Cyprus

EU Contribution

€ 314 645

BEN-GURION UNIVERSITY OF THE NEGEV

Israel

EU Contribution

€ 703 680

PANEPISTIMIAKO GENIKO NOSOKOMEIO IRAKLEIOU

Greece

EU Contribution

€ 374 625

OROBIX SRL

Italy

EU Contribution

€ 71 280

Project information

Grant agreement ID: 602714

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 032 384

  • EU contribution

    € 5 443 350

Coordinated by:

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy